Effects of hypertension and exercise on cardiac proteome remodelling

Bernardo A Petriz1, Octavio L Franco1

  • 1Centro de Análises Proteômicas e Bioquímicas, Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília SGAN, Quadra 916, Módulo B, Avenida W5 Norte, 70.790-160 Brasília, DF, Brazil.

Insights

Hypertension causes cardiac hypertrophy through adverse molecular changes. Exercise training, however, induces physiologic cardiac hypertrophy with improved function and cardioprotection, modulating heart proteomes differently.

Area of Science:

  • Cardiovascular Biology
  • Proteomics
  • Molecular Medicine

Background:

  • Left ventricle hypertrophy is a common cardiac response to pressure overload, often linked to hypertension.
  • Hypertensive cardiac hypertrophy involves detrimental molecular signaling, gene expression, and proteome alterations.
  • Key molecular targets in pathologic cardiac hypertrophy include angiotensin II, endothelin-1, and isoproterenol.

Purpose of the Study:

  • To review and compare molecular and proteomic alterations in hypertensive vs. exercise-induced cardiac hypertrophy.
  • To examine proteomic research on cardiac hypertrophy and hypertension's effects on other organs.

Main Methods:

  • Review of existing proteomic and molecular studies on cardiac hypertrophy.
  • Analysis of protein alterations in hypertension-induced and exercise-induced cardiac hypertrophy.
  • Examination of proteomic data related to hypertension's impact on other organs.

Main Results:

  • Hypertension-induced hypertrophy involves altered metabolic, contractile, and stress-related proteins.
  • Exercise-induced hypertrophy is associated with improved cardiac function and cardioprotective proteomic changes.
  • Proteomes are modulated differently between pathologic (hypertensive) and physiologic (exercise) cardiac hypertrophy.

Conclusions:

  • Cardiac hypertrophy manifests differently under hypertensive pressure overload versus exercise training.
  • Exercise-induced cardiac hypertrophy offers cardioprotective benefits through distinct proteomic adaptations.
  • Proteomic insights are crucial for understanding and differentiating cardiac hypertrophy types.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.6K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.7K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
751